Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Podcasts|November 19, 2026 (Updated: November 19, 2026)

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics

Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Today: an ADC that targets the tumor’s surroundings, a new way to block complement in myasthenia gravis, and bispecifics designed to hit only cells that carry two targets at once.

First, Pyxis Oncology reported updated phase 1 data for micvotabart pelidotin, or MICVO. Instead of a tumor-cell receptor, MICVO binds extradomain-B of fibronectin, a component of the tumor extracellular matrix. In 33 patients with previously treated recurrent or metastatic head and neck cancer, the confirmed response rate was 39%, with a median duration of response of 9.2 months. The trial is single-arm, and Pyxis plans to start a global phase 3 trial in mid-2027. www.biopharminternational.com

Next, FDA has approved Regeneron’s Livsayis, or cemdisiran, the first RNAi therapeutic for generalized myasthenia gravis. It treats adults who are anti-AChR antibody positive. It silences the mRNA that encodes complement component C5, which differs from antibody-based C5 inhibitors that bind the protein itself. It is given as a subcutaneous injection four times a year. The approval comes just days after FDA approved AstraZeneca’s antibody-based C5 inhibitor Klygefa for the same population. www.biopharminternational.com

And finally, AbbVie and DISCO Pharmaceuticals have agreed to develop AND-gated bispecifics for solid tumors. The ADCs and T-cell engagers would bind two targets at once, aiming to spare healthy tissue that expresses only one. DISCO receives $40 million upfront and is eligible for up to $2.5 billion in milestones. The work is at the discovery stage, and the targets have not been disclosed. www.biopharminternational.com

That’s today’s BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways

  • New ADC targets: MICVO’s early data support targeting the tumor matrix, but phase 3 data will be needed to confirm it.
  • Competing modalities: Myasthenia gravis now has two newly approved C5 inhibitors, an antibody given weekly and an siRNA given four times a year.
  • Precision targeting: AbbVie’s deal shows investment in bispecifics engineered to tell tumor cells from healthy ones.

Related to this article

The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.